✦ LIBER ✦

Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study

✍ Scribed by Michael W. Fried; Mitchell L. Shiffman; Rejender K. Reddy; Coleman Smith; George Marino; Femando Goncales Jr; Dieter Haeussinger; Moises Diago; Giampietro Carosl; Jean-Pierre Zarski; Joseph Hoffman; Jian Yu

Book ID: 119429137
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 196 KB
Volume: 120
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(08)80271-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pegylated (40 KDA) interferon alfa-2a (P

Pegylated (40 KDA) interferon alfa-2a (PEGASYS®) in new combination therapies: a report of a randomized, multicenter efficacy and safety study

✍ A.M. Di Bisceglie; D.E. Bernstein; V.R. Rustgi; N. Gitlin; L.J. Jeffers; D. Simo 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Pegylated (40 kDa) interferon alfa-2a (P

Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with Ribavirin, mycophenolate motelil (CellCept®), amantadine, or amantadine plus ribavirin in patients that relapsed on rebetronTM therapy: A preliminary report of a randomized, multicenter efficacy and safety study

✍ Herrine, Steven K.; Brown, Robert; Esposito, Stephen; Lok, Anna; Galati, Joseph 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 169 KB

Pegylated (40 kDa) interferon alfa-2a (P

Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin, mycophenolate mofetil (CellCept®), amantadine, or amantadine plus ribavirin in patients that did not respond to rebetronTM therapy: A preliminary report of a randomized, multicenter study

✍ Afdhal, Nezam; Flamm, Steven; Imperial, Joanne; Malet, Peter F.; Tong, Myron; Ca 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 157 KB

Peginterferon alfa-2A (40 KD) (PEGASYS)

Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose

✍ S.J. Hadziyannis; H. Cheinquer; T. Morgan; M. Diago; D.M. Jensen; H. Sette Jr.; 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 147 KB

319 Treatment with pegylated-interferon

319 Treatment with pegylated-interferon alfa 2B in relapsers to standard interferon + ribavirin in chronic hepatitis C: Efficacy and safety results from a randomized multicentric French study

✍ Isabelle Portal; Danielle Botta-Fridlund; Marc Bouliere; Michel Rotily; Philippe 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

987 Peginterferon alfa-2A (40KD) (PEGASY

987 Peginterferon alfa-2A (40KD) (PEGASYS®) and ribavirin (COPEGUS®) in patients with HIV/HCV coinfection: interim results of a randomized, multicenter study from spain

✍ HERNANDEZQUERO, J; PEREZGUZMAN, E; LOZANO, F; PARRA, J; DELMARALONSO, M 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB